Sino Biopharmaceutical

HKG:1177 · KYG8167W1380

PharmaceuticalsX-Large

360

Value60

Profit price53

EV / EBIT82

Price / Owner Earnings24

Cash yield63

Owner Earnings Yield38

Dividend Yield87

Sales & asset price60

Price/Sales50

EV / Gross Profit91

Price/Book38

Quality42

Returns on capital30

Return on Capital35

Cash Return on Capital14

Return on Equity41

Profit margins44

EBIT Margin52

Gross Profitability36

Cash backing48

Cash Conversion98

Accruals29

Owner Earnings Margin17

Growth43

Sales growth51

Profit growth57

Profit Growth77

Long-Term EPS Growth84

Owner Earnings Growth9

Reinvestment77

Price momentum69

Safety57

Debt load38

Debt serviceability51

Refinancing1

Debt Payback100

Liquidity77

Sentiment53

Analyst ratings65

Expectations trend86

Opinion Changes71

Price Target Upside100

Market mood61

Value Creation14/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Sino Biopharmaceutical generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryHong Kong SAR China

IndustryPharmaceuticals

SizeX-Large

TypePublic Company

ExchangeSEHK

Founded2000

Employees29

Websitesinobiopharm.com

ISINKYG8167W1380

Last UpdateApr 2, 2026

Indices

Hang Seng (Hong Kong)

Themes

Pain ManagementGastroenterologyRespiratoryHepatologyOncologySurgeryHealth CareHealth DiagnosticsHospitalMedicalPharmaceutical

Description

Sino Biopharmaceutical Limited is a leading company primarily engaged in the manufacturing and distribution of modernized Chinese medicines and chemical medicines. It operates within the pharmaceutical sector and focuses on the research and developme…

Analysis

Middle-of-the-road

Sino Biopharmaceutical Limited is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is expensive. You pay 35.8× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 14% yearly growth; analysts expect 20%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 14/20 on our value-creation score: strong value creator.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sino Biopharmaceutical with its peers

Dong-A Socio

KSC:000640

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Kwangdong Pharmaceutical

KSC:009290

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Hyundai Pharmaceutical

KSC:004310

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Aprogen Biologics

KSC:003060

CountrySouth Korea

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Dongwha Pharm

KSC:000020

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Sumitomo Dainippon Pharma

TYO:4506

CountryJapan

IndustryPharmaceuticals

SizeLarge

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →